Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis

Tan, Kun; Ji, Liang; Teng, Xiaochun; Wang, Xiaochun; Zhang, Jingyan; Yuan, Xuefeng; Fan, Xionglin

doi:10.4161/hv.26969

Cited by 9 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, DMT liposome-adjuvanted rRv0572c can enhance the Th1 immune response induced by BCG, with elicitation of a limited humoral immune response. One study has reported that the mRNA expression of antigen-specific cytokines in the lungs of mice immunized with BCG prime-pcD685A booster increased more significantly than BCG when adopting subcutaneous immunization [ 31 ]. Combined with our results, the antigen-specific expression of pulmonary cytokine mRNA can also be enhanced via subcutaneous immunization.…”

Section: Discussionmentioning

confidence: 99%

Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster

Mao

Xing

et al. 2022

Tuberculosis

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster

Mao

Xing

et al. 2022

Tuberculosis

Self Cite

View full text Add to dashboard Cite

“…The transcripts of Ag85A, Ag85B, and HspX in ~10 6 CFU of ABX, each individual rBCGs, and BCG were determined by qRT-PCR using SYBR ® Select Master Mix (Invitrogen Life Technologies, Grand Island, NY, USA). The primer sets and PCR parameters were listed in Table 1, as previously described (Tan et al, 2014). The abundance of target transcript was normalized to the transcript level of endogenous sigA gene.…”

Section: Bacterial Culture and Preparation Of Abxmentioning

confidence: 99%

“…Recombinant BCG strains expressing multiple antigens in one strain (Sun et al, 2009;Wang et al, 2012) or as fusion proteins (Palendira et al, 2005;Tan et al, 2014) are currently being tested, and the protective efficacies of rBCG could be affected by many factors (Dennehy and Williamson, 2005), including the choice of antigens and expression strategy. We have previously reported that three rBCG strains, rBCG::X (Shi et al, 2010), rBCG::85A, and rBCG::85B (Wang et al, 2012) exhibited a better immune protection than BCG in mice.…”

Section: Introductionmentioning

confidence: 99%

Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis

Teng

Yuan

et al. 2015

Molecular Immunology

Self Cite

View full text Add to dashboard Cite

Although Bacillus Calmette-Guérin (BCG) vaccine confers protection from Mycobacterium tuberculosis infection in children, its immune protection gradually wanes over time, and consequently leads to an inability to prevent the reactivation of latent infection of M. tuberculosis. Therefore, improving BCG for better control of tuberculosis (TB) is urgently needed. We thus hypothesized that recombinant BCG overexpressing immunodominant antigens expressed at different growth stages of M. tuberculosis could provide a more comprehensive protection against primary and latent M. tuberculosis infection. Here, a novel cocktail of recombinant BCG (rBCG) strains, namely ABX, was produced by combining rBCG::85A, rBCG::85B, and rBCG::X, which overexpressed respective multistage antigens Ag85A, Ag85B, and HspX of M. tuberculosis. Our results showed that ABX was able to induce a stronger immune protection than individual rBCGs or BCG against primary TB infection in C57BL/6 mice. Mechanistically, the immune protection was attributed to stronger antigen-specific CD4(+) Th1 responses, higher numbers of IFN-γ(+) CD4(+) TEM and IL-2(+) CD8(+) TCM cells elicited by ABX. These findings thus provide a novel strategy for the improvement of BCG efficacy and potentially a promising prophylactic TB vaccine candidate, warranting further investigation.

show abstract

“…Consequently, it has not had a major effect on the global burden of TB ( Fine, 1995 ; Trunz et al, 2006 ; Young et al, 2008 ; Mangtani et al, 2014 ; McShane, 2014 ). Re-vaccination to boost the initial immune responses is an attractive strategy ( Cervantes-Villagrana et al, 2013 ; Tan et al, 2014 ) but homologous boosting with BCG is of limited benefit ( Nemes et al, 2018 ). Heterologous prime–boost strategies that rely on selected antigens that are present in BCG and Mtb may be an optimal approach.…”

Section: Introductionmentioning

confidence: 99%

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

The development of heterologous prime-boost regimens utilizing Bacille Calmette–Guerin (BCG) as the priming vaccine is a promising approach to improve the efficacy of vaccination against tuberculosis (TB). In this study, we examined the ability of a DNA vaccine that expressed a fusion of antigens Rv2299c and Ag85A to boost BCG immunity and protection against Mycobacterium tuberculosis (Mtb) in Balb/c mice. The fusion DNA vaccine was moderately immunogenic and afforded some protection when used on its own. After a priming BCG vaccination, the DNA boost significantly amplified Th1-type cell-mediated immunity compared to that resulting from either BCG or DNA immunization. In the DNA-boosted mice, Ag-specific CD4+ and CD8+ T cells that were mono-positive for IFN-γ alone were the most prominently expanded in infected lungs. The protective efficacy afforded by BCG against challenge infection was greatly improved by the DNA boost; bacterial loads were significantly reduced in both spleen and lung and histological damage in the lung was less. The use of a DNA vaccine containing the fusion antigens Rv2299c and Ag85A to boost BCG may be a good choice for the rational design of an efficient vaccination strategy against TB.

show abstract

Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis

Cited by 9 publications

References 43 publications

Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster

Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster

Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

Contact Info

Product

Resources

About